References
1. Foster, C., L. Smith, and R. Alemzadeh, Excess serum uric acid is associated with metabolic syndrome in obese adolescent patients.
2. Liu, F., et al., Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008-2012). Lipids Health Dis, 2020. 19 (1): p. 58.
3. Derosa, G., P. Maffioli, and A. Sahebkar, Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res, 2015. 102 : p. 63-70.
4. Katsiki, N., et al., Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol, 2011. 9 (6): p. 698-705.
5. Catanzaro, R., et al., Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population. Acta Clin Belg, 2020: p. 1-6.
6. Khedr, N.F., A.M. Ebeid, and R.M. Khalil, New insights into weight management by orlistat in comparison with cinnamon as a natural lipase inhibitor. Endocrine, 2020. 67 (1): p. 109-116.
7. Holmback, U., et al., Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obes Sci Pract, 2020. 6 (3): p. 313-323.
8. Chales, G., How should we manage asymptomatic hyperuricemia? Joint Bone Spine, 2019. 86 (4): p. 437-443.
9. Norgren, S., et al., Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatrica, 2003. 92 (6): p. 666-670.
10. Diamanti-Kandarakis, E., et al., Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism, 2006. 55 (4): p. 494-500.
11. Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 2015.4 : p. 1.
12. Higgins, J.P., et al., Cochrane handbook for systematic reviews of interventions. 2019: John Wiley & Sons.
13. Higgins, J.P., et al., The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj, 2011. 343 : p. d5928.
14. DerSimonian, R. and R. Kacker, Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trial 28 (2): 105–114. 2007.
15. Hozo, S.P., B. Djulbegovic, and I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology, 2005. 5 (1): p. 13.
16. Higgins, J.P. and S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat Med, 2002. 21 (11): p. 1539-58.
17. Egger, M., et al., Bias in meta-analysis detected by a simple, graphical test. Bmj, 1997. 315 (7109): p. 629-634.
18. Duval, S. and R. Tweedie, Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 2000. 56 (2): p. 455-63.
19. Borenstein, M., et al., Comprehensive meta-analysis version 2. Biostat. Englewood NJ, 2005.
20. Guy‐Grand, B., et al., Effects of orlistat on obesity‐related diseases–a six‐month randomized trial. Diabetes, Obesity and Metabolism, 2004. 6 (5): p. 375-383.
21. Didangelos, T.P., et al., The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin, 2004. 20 (9): p. 1393-401.
22. Cocco, G., S. Pandolfi, and V. Rousson, Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome. Heart Drug, 2005. 5 (2): p. 68-74.
23. Filippatos, T.D., et al., Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin, 2005. 21 (12): p. 1997-2006.
24. Nakou, E.S., et al., The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin, 2008. 24 (7): p. 1919-29.
25. Song, J., et al., Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol, 2018. 34 (5): p. 413-417.
26. Ye, J., et al., Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol, 2019. 12 : p. 1756284819879047.
27. Yeo, C., et al., Impact of bariatric surgery on serum uric acid levels and the incidence of gout—A meta‐analysis. Obesity Reviews, 2019. 20 (12): p. 1759-1770.
28. Chen, S., et al., Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. Medicine (Baltimore), 2020. 99 (11): p. e19088.
29. Kane, J.A., et al., Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. Int J Clin Res Trials, 2019. 4 (1).
30. Dai, H.X., et al., Higher Levels of High-Sensitivity C-Reactive Protein Is Positively Associated with the Incidence of Hyperuricemia in Chinese Population: A Report from the China Health and Retirement Longitudinal Study. Mediators Inflamm, 2020. 2020 : p. 3854982.
31. Carnicelli, A.P., et al., Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. Am J Med, 2020.
32. Derosa, G., P. Maffioli, and A. Sahebkar, Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. Br J Clin Pharmacol, 2016.81 (5): p. 819-34.
Table 1.Characteristices of the included studies